Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?

Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In ...

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar ...

Gilead Sciences is on an FDA approval hot streak. Should you buy the stock like there's no tomorrow?

The company's recent momentum continues unabated.
Hosted on MSN

Gilead Sciences, Inc. (GILD) is attracting investor attention: Here is what you should know

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...
Seeking Alpha

What Gilead Is Getting Through The Acquisition Of Arcellx

M&A is back in the biotech industry. After a disappointing January and almost no activity to date in February, Gilead (GILD) brings some joy back with up to $7.8 billion acquisition of partner Arcellx ...
BioSpace

Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push

Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ...
Seeking Alpha

Gilead: Remdesivir Is Not The Only Reason To Buy

Gilead Sciences currently owns the most effective treatment for coronavirus, and has been expanding its viral treatment business over the past twenty years. Despite Gilead’s growth, the market ...